HEB Share Price

Open 0.89 Change Price %
High 0.89 1 Day 0.04 4.88
Low 0.80 1 Week 0.04 4.88
Close 0.86 1 Month -0.02 -2.27
Volume 113065 1 Year 0.74 616.67
52 Week High 2.00
52 Week Low 0.06
HEB Important Levels
Resistance 2 0.94
Resistance 1 0.91
Pivot 0.85
Support 1 0.81
Support 2 0.78
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
NGD 3.93 5.65%
NGD 3.93 5.65%
NAK 1.52 7.04%
NAK 1.52 7.04%
PBTH 8.23 0.37%
PLX 0.30 -9.09%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
SIF 8.65 -18.40%
WGA 0.18 -18.18%
More..

Hemispherx BioPharma, Inc. (AMEX: HEB)

HEB Technical Analysis 2
As on 7th Dec 2016 HEB Share Price closed @ 0.86 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.43 & Strong Sell for SHORT-TERM with Stoploss of 1.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
HEB Target for December
1st Target up-side 0.98
2nd Target up-side 1.09
3rd Target up-side 1.2
1st Target down-side 0.66
2nd Target down-side 0.55
3rd Target down-side 0.44
HEB Other Details
Segment EQ
Market Capital 115221192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.hemispherx.net
HEB Address
HEB
One Penn Center
1617 JFK Boulevard
Philadelphia, PA 19103
United States
Phone: 215-988-0080
Fax: 215-988-1739
Interactive Technical Analysis Chart Hemispherx BioPharma, Inc. ( HEB AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hemispherx BioPharma, Inc.
HEB Business Profile
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.